BRTX · BioRestorative Therapies, Inc.

0001493152-26-023126

Summary

BioRestorative Therapies reported a mixed Q1 with revenue and gross profit declines offset by sharply reduced operating and net losses, driven by lower stock-based compensation, amid ongoing cash burn to fund clinical trials.

Key takeaways

Gross profit fell 28.5% to $15.8K despite resilient 68.1% margin, reflecting topline pressure from reduced royalties.
Net loss narrowed 59.7% to -$2.2M from -$5.3M, improving diluted EPS 81.2% to -$0.12 from -$0.64.
Operating cash use rose to -$3.8M from -$2.8M, funding clinical trials, working capital, and $36K capex unchanged year-over-year.
Free cash flow was -$3.8M as financing and investing inflows supported net cash increase despite operating burn.

Full analysis

Management emphasizes that operating needs encompass clinical trial funding, working capital, and capex, anticipating continued net losses and negative operating cash flows through 2026 and beyond to execute development plans and potential strategic initiatives. This positions BRTX at a pivotal juncture where trial progress and cost management will shape liquidity and valuation, consistent with biotech norms of high burn for high-upside therapies in regenerative medicine.